• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

与重度哮喘控制相关的因素。

Factors associated with the control of severe asthma.

作者信息

Hermosa Juan Luis Rodriguez, Sánchez Carlos Barcina, Rubio Myriam Calle, Mínguez Mercedes Muñoz, Walther Jose Luis Alvarez-Sala

机构信息

Department of Neumology, Hospital Clinico San Carlos, Madrid 28003, Spain.

出版信息

J Asthma. 2010 Mar;47(2):124-30. doi: 10.3109/02770900903518835.

DOI:10.3109/02770900903518835
PMID:20170317
Abstract

INTRODUCTION

Control is a priority treatment objective in asthma, and classification based on control is recommended in the follow-up of asthmatic patients. Different factors affect this control, and there are several regional differences, both in terms of prevalence and in terms of management and degree of control.

OBJECTIVE

To evaluate the factors associated with control of severe asthma in routine clinical practice.

MATERIAL AND METHODS

This was a prospective, cross-sectional, observational study of patients with severe asthma who were receiving treatment with a fixed combination of a corticosteroid (at least 800 microg/day of budesonide or equivalent) and an inhaled beta(2)-adrenergic agonist in respiratory medicine and allergology clinics throughout Spain. The authors collected demographic and socioeconomic data, as well as clinical data on asthma. The patients also completed a self-administered validated questionnaire-the Asthma Control Questionnaire (ACQ)-about the control of their asthma.

RESULTS

The authors included 1471 patients, of whom 1224 (83%) were valid for the final analysis. Women accounted for 61%. Mean age was 51 +/- 16 years. The mean number of exacerbations during the previous year was 2.0 +/- 2.0. The global score on the ACQ was 1.8 +/- 1.1 (0 = no symptoms; 6 = maximum number of symptoms). Only 20.4% of patients were well controlled (ACQ < 0.75), and 55.7% of patients were poorly controlled (ACQ > 1.5). The multivariate analysis revealed that the variable with the greatest effect on control of asthma was the number of exacerbations during the previous year: when the number of exacerbations increased from 0 to 1 or more, the ACQ score increased by 0.56 points. Employed patients had a mean of 0.23 points less (better control) than unemployed and retired patients. Control of asthma was also significantly affected by adherence to treatment, patient knowledge of the disease, body mass index, gender, and number of visits to a physician in the previous 3 months.

CONCLUSIONS

Many patients with severe asthma have poor control of their disease. The number of exacerbations is the variable with the greatest effect on control of asthma. Knowledge of the disease and adherence to treatment are associated with better control.

摘要

引言

控制是哮喘治疗的首要目标,建议在哮喘患者的随访中基于控制情况进行分类。不同因素影响这一控制情况,在患病率、管理以及控制程度方面均存在一些地区差异。

目的

评估在常规临床实践中与重度哮喘控制相关的因素。

材料与方法

这是一项针对重度哮喘患者的前瞻性、横断面观察性研究,这些患者在西班牙各地的呼吸内科和变态反应科诊所接受皮质类固醇(至少800微克/天布地奈德或等效药物)与吸入型β₂肾上腺素能激动剂的固定复方治疗。作者收集了人口统计学和社会经济数据以及哮喘的临床数据。患者还完成了一份关于哮喘控制情况的自我管理有效问卷——哮喘控制问卷(ACQ)。

结果

作者纳入了1471例患者,其中1224例(83%)可用于最终分析。女性占61%。平均年龄为51±16岁。前一年的平均发作次数为2.0±2.0次。ACQ的总体评分为1.8±1.1(0 = 无症状;6 = 症状最多)。只有20.4%的患者控制良好(ACQ < 0.75),55.7%的患者控制不佳(ACQ > 1.5)。多因素分析显示,对哮喘控制影响最大的变量是前一年的发作次数:当发作次数从0次增加到1次或更多时,ACQ评分增加0.56分。在职患者的平均得分比失业和退休患者低0.23分(控制更好)。哮喘控制还受到治疗依从性、患者对疾病的了解、体重指数、性别以及前3个月看医生次数的显著影响。

结论

许多重度哮喘患者疾病控制不佳。发作次数是对哮喘控制影响最大的变量。对疾病的了解和治疗依从性与更好的控制相关。

相似文献

1
Factors associated with the control of severe asthma.与重度哮喘控制相关的因素。
J Asthma. 2010 Mar;47(2):124-30. doi: 10.3109/02770900903518835.
2
Control of persistent asthma in Spain: associated factors.西班牙持续性哮喘的控制:相关因素
J Asthma. 2008 Nov;45(9):740-6. doi: 10.1080/02770900802216783.
3
The impact of alexithymia on asthma patient management and communication with health care providers: a pilot study.述情障碍对哮喘患者管理及与医护人员沟通的影响:一项试点研究。
J Asthma. 2009 Mar;46(2):126-9. doi: 10.1080/02770900802468525.
4
Factors associated with asthma control.与哮喘控制相关的因素。
J Asthma. 2005 Oct;42(8):659-65. doi: 10.1080/02770900500264903.
5
Determinants of asthma control in tertiary level in Turkey: a cross-sectional multicenter survey.土耳其三级医疗机构中哮喘控制的决定因素:一项横断面多中心调查。
J Asthma. 2010 Jun;47(5):557-62. doi: 10.3109/02770901003692777.
6
Forced expiratory volume in 1 second percentage improves the classification of severity among children with asthma.一秒用力呼气容积百分比可改善哮喘儿童严重程度的分级。
Pediatrics. 2006 Aug;118(2):e347-55. doi: 10.1542/peds.2005-2962. Epub 2006 Jul 24.
7
[Factors associated with asthma control in primary care patients: the CHAS study].[基层医疗患者哮喘控制的相关因素:CHAS研究]
Arch Bronconeumol. 2010 Jul;46(7):358-63. doi: 10.1016/j.arbres.2010.01.007. Epub 2010 Mar 15.
8
Can the Asthma Control Questionnaire be used to differentiate between patients with controlled and uncontrolled asthma symptoms? A pilot study.哮喘控制问卷能否用于区分哮喘症状得到控制和未得到控制的患者?一项初步研究。
Fam Pract. 2006 Dec;23(6):674-81. doi: 10.1093/fampra/cml041. Epub 2006 Jul 31.
9
Association between episodes of upper respiratory infection and exacerbations in adult patients with asthma.成年哮喘患者上呼吸道感染发作与病情加重之间的关联
J Asthma. 2012 Apr;49(3):253-9. doi: 10.3109/02770903.2012.661009. Epub 2012 Feb 29.
10
Cut-off points for defining asthma control in three versions of the Asthma Control Questionnaire.哮喘控制问卷三个版本中用于定义哮喘控制的切点。
J Asthma. 2010 Oct;47(8):865-70. doi: 10.3109/02770903.2010.491149.

引用本文的文献

1
Semi-Mechanistic Population Pharmacokinetic/Pharmacodynamic (PK/PD) Modeling of Dupilumab on Pre-Bronchodilator Forced Expiratory Volume in 1 Second (FEV) in Uncontrolled Moderate-To-Severe Asthma.度普利尤单抗对未控制的中度至重度哮喘患者支气管扩张剂使用前1秒用力呼气容积(FEV)的半机制群体药代动力学/药效学(PK/PD)建模
CPT Pharmacometrics Syst Pharmacol. 2025 Aug;14(8):1370-1380. doi: 10.1002/psp4.70057. Epub 2025 Jun 19.
2
Describing the burden of moderate exacerbations in patients with asthma from the Extended Salford Lung Study (Ext-SLS): a retrospective cohort study.描述来自索尔福德肺脏扩展研究(Ext-SLS)的哮喘患者中度加重的负担:一项回顾性队列研究。
Respir Res. 2025 Mar 29;26(1):121. doi: 10.1186/s12931-025-03199-5.
3
Burden of illness among patients with asthma prescribed inhaled corticosteroids/long-acting β-agonists.
使用吸入性糖皮质激素/长效β受体激动剂的哮喘患者的疾病负担
NPJ Prim Care Respir Med. 2025 Feb 26;35(1):10. doi: 10.1038/s41533-024-00402-w.
4
House dust mite allergy in Malaysia: review of research gaps in the current scenario and the way forward.马来西亚的屋尘螨过敏:当前研究空白的综述及未来发展方向。
Exp Appl Acarol. 2023 Dec;91(4):509-539. doi: 10.1007/s10493-023-00857-5. Epub 2023 Nov 23.
5
[Asthma 2020 Nursing Consensus Document].[《2020年哮喘护理共识文件》]
Open Respir Arch. 2021 Jan 8;3(1):100079. doi: 10.1016/j.opresp.2020.100079. eCollection 2021 Jan-Mar.
6
Population Pharmacokinetics and Exposure-Response Relationships of Astegolimab in Patients With Severe Asthma.重度哮喘患者阿替利珠单抗的群体药代动力学和暴露-反应关系。
J Clin Pharmacol. 2022 Jul;62(7):905-917. doi: 10.1002/jcph.2021. Epub 2022 Feb 9.
7
Population repeated time-to-event analysis of exacerbations in asthma patients: A novel approach for predicting asthma exacerbations based on biomarkers, spirometry, and diaries/questionnaires.人群重复时间事件分析在哮喘患者中的急性发作:一种基于生物标志物、肺功能和日记/问卷预测哮喘急性发作的新方法。
CPT Pharmacometrics Syst Pharmacol. 2021 Oct;10(10):1221-1235. doi: 10.1002/psp4.12690. Epub 2021 Aug 5.
8
Population pharmacokinetic analysis of dupilumab in adult and adolescent patients with asthma.成人和青少年哮喘患者度普利尤单抗的群体药代动力学分析。
CPT Pharmacometrics Syst Pharmacol. 2021 Aug;10(8):941-952. doi: 10.1002/psp4.12667. Epub 2021 Jul 27.
9
Dupilumab is effective in type 2-high asthma patients receiving high-dose inhaled corticosteroids at baseline.度普利尤单抗对基线时接受高剂量吸入性糖皮质激素治疗的2型重度哮喘患者有效。
Allergy. 2021 Jan;76(1):269-280. doi: 10.1111/all.14611. Epub 2020 Oct 21.
10
Updated Evaluation of Dupilumab in the Treatment of Asthma: Patient Selection and Reported Outcomes.度普利尤单抗治疗哮喘的最新评估:患者选择与报告的结局
Ther Clin Risk Manag. 2020 Mar 4;16:181-187. doi: 10.2147/TCRM.S192392. eCollection 2020.